In conclusion, we report that YM155 treatment can kill esophageal cancer cells by causing DNA damage, PARP-1 hyper-activity, and AIF translocation leading to PARP-1-dependent parthanatos cell death and that it reduced tumor burden in both in vitro and in animal models in vivo of esophageal cancer. The gene discussed is PARP1; the disease is esophageal cancer.